Home 2016-10-15T14:05:40+00:00

Combatting the 21st century global public health problems through revolutionary i-αVLP Technology.

412, 2017

PNAS online – 4 December 2017

“Structural studies of Chikungunya virus maturation” Moh Lan Yap, Thomas Klose, Akane Urakami, S. Saif Hasan, Wataru Akahata, and Michael G. Rossmann http://www.pnas.org/content/early/2017/11/29/1713166114.abstract?sid=89ef6c8b-994e-400d-af12-3726d0d40bbc

610, 2017

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP Therapeutics, LLC (“VLP”), a biotechnology

2709, 2017

Journal of Virology – 27 September 2017

“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata   http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.